ENHANCING AN OXIDATIVE “TROJAN HORSE” ACTION OF VITAMIN C WITH ARSENIC TRIOXIDE FOR EFFECTIVE SUPPRESSION OF KRAS-MUTANT CANCERS: A PROMISING PATH AT THE BEDSIDE
| dc.contributor.author | Burska, Agata N. | |
| dc.contributor.author | Ilyassova, Bayansulu | |
| dc.contributor.author | Dildabek, Aruzhan | |
| dc.contributor.author | Khamijan, Medina | |
| dc.contributor.author | Begimbetova, Dinara | |
| dc.contributor.author | Molnár, Ferdinand | |
| dc.date.accessioned | 2023-04-07T08:17:03Z | |
| dc.date.available | 2023-04-07T08:17:03Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | The turn-on mutations of the KRAS gene, coding a small GTPase coupling growth factor signaling, are contributing to nearly 25% of all human cancers, leading to highly malignant tumors with poor outcomes. Targeting of oncogenic KRAS remains a most challenging task in oncology. Recently, the specific G12C mutant KRAS inhibitors have been developed but with a limited clinical outcome because they acquire drug resistance. Alternatively, exploiting a metabolic breach of KRAS-mutant cancer cells related to a glucose-dependent sensitivity to oxidative stress is becoming a promising indirect cancer targeting approach. Here, we discuss the use of a vitamin C (VC) acting in high dose as an oxidative “Trojan horse” agent for KRAS-mutant cancer cells that can be potentiated with another oxidizing drug arsenic trioxide (ATO) to obtain a potent and selective cytotoxic impact. Moreover, we outline the advantages of VC’s non-natural enantiomer, D-VC, because of its distinctive pharmacokinetics and lower toxicity. Thus, the D-VC and ATO combination shows a promising path to treat KRAS-mutant cancers in clinical settings. | en_US |
| dc.identifier.citation | Burska, A., Ilyassova, B., Dildabek, A., Khamijan, M., Begimbetova, D., Molnár, F., & Sarbassov, D. D. (2022). Enhancing an Oxidative “Trojan Horse” Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside. Cells, 11(21), 3454. https://doi.org/10.3390/cells11213454 | en_US |
| dc.identifier.uri | http://nur.nu.edu.kz/handle/123456789/7008 | |
| dc.language.iso | en | en_US |
| dc.publisher | Cell | en_US |
| dc.rights | Attribution-NonCommercial-ShareAlike 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/us/ | * |
| dc.subject | Type of access: Open Access | en_US |
| dc.subject | Kirsten rat sarcoma (KRAS) mutant ancers | en_US |
| dc.subject | Warburg effect | en_US |
| dc.subject | oxidative stress | en_US |
| dc.subject | arsenic trioxide (ATO) | en_US |
| dc.subject | vitamin C (VC also known as ascorbic acid) | en_US |
| dc.subject | reactive oxygen species (ROS) | en_US |
| dc.subject | suicidal ROS production by mitochondrial (SRPM) | en_US |
| dc.title | ENHANCING AN OXIDATIVE “TROJAN HORSE” ACTION OF VITAMIN C WITH ARSENIC TRIOXIDE FOR EFFECTIVE SUPPRESSION OF KRAS-MUTANT CANCERS: A PROMISING PATH AT THE BEDSIDE | en_US |
| dc.type | Article | en_US |
| workflow.import.source | science |